Cargando…
Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies
Since 1985 when the first agent targeting antigens on the surface of lymphocytes was approved (muromonab-CD3), a multitude of such therapies have been used in children with hematologic malignancies. A detailed literature review until January 2021 was conducted regarding pediatric patient populations...
Autores principales: | Kyriakidis, Ioannis, Vasileiou, Eleni, Rossig, Claudia, Roilides, Emmanuel, Groll, Andreas H., Tragiannidis, Athanasios |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7999508/ https://www.ncbi.nlm.nih.gov/pubmed/33807678 http://dx.doi.org/10.3390/jof7030186 |
Ejemplares similares
-
Infectious Complications of Targeted Therapies in Children with Leukemias and Lymphomas
por: Kyriakidis, Ioannis, et al.
Publicado: (2022) -
Acinetobacter baumannii Antibiotic Resistance Mechanisms
por: Kyriakidis, Ioannis, et al.
Publicado: (2021) -
Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies
por: Wang, Hao, et al.
Publicado: (2019) -
Invasive fungal infections in a pediatric hematology-oncology department: A 16-year retrospective study
por: Kazakou, Nikoleta, et al.
Publicado: (2020) -
Extrahepatic Biliary Atresia, Liver Function Tests, and Hemoglobin Variants
por: Kyriakidis, Ioannis, et al.
Publicado: (2018)